Inventiva S.A. American Depository Shares (IVA) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Pharming Group N.V. (PHAR) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, losing 33.1% versus a loss of 39.4%. Over five years, PHAR leads with a -0.6% price change compared with -79.4% for IVA. Inventiva S.A. American Depository Shares is the larger company by market cap ($694.5 million vs $662.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVA | PHAR |
|---|---|---|
| Share price | $2.94 | $9.36 |
| Market cap | $694.49M | $662.48M |
| 1-day change | -5.47% | -2.40% |
| YTD return | -36.77% | -47.03% |
| 1-year return | -39.38% | -33.14% |
| 5-year return | -79.35% | -0.64% |
| P/E ratio (TTM) | — | 72.00 |
| Forward P/E | — | 142.90 |
| EPS (TTM) | $-0.62 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $376.13M |
| Revenue growth (YoY) | — | +26.56% |
| Net income (latest FY) | $-49.63M | $2.85M |
| Gross margin | — | 87.90% |
| Operating margin | — | 6.87% |
| Net margin | — | 0.76% |
| 52-week high | $7.98 | $21.34 |
| 52-week low | $2.82 | $9.31 |
| Distance from 52-week high | -63.17% | -56.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +417.01% | +266.99% |
| Average volume | 1.61M | 23.08K |
| Shares outstanding | 236.22M | 70.78M |
| Employees | 87 | 407 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
IVA vs PHAR FAQ
Which is bigger, Inventiva S.A. American Depository Shares or Pharming Group N.V.?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $694.49M compared with $662.48M for Pharming Group N.V. (PHAR).
Which stock has performed better over the past year, IVA or PHAR?
PHAR returned -33.14% over the past 12 months, compared with -39.38% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Inventiva S.A. American Depository Shares and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.